Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

Anaplastic thyroid cancer (ATC) has a median survival less than 5 months and, to date, no effective therapy exists. Taxanes have recently been stated as the main drug treatment for ATC, and the histone deacetylase inhibitor valproic acid efficiently potentiates the effects of paclitaxel in vitro. Ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Maria Graziella, Pugliese, Mariateresa, Gallo, Marco, Brignardello, Enrico, Milla, Paola, Orlandi, Fabio, Limone, Paolo Piero, Arvat, Emanuela, Boccuzzi, Giuseppe, Piovesan, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059567/
https://www.ncbi.nlm.nih.gov/pubmed/27766105
http://dx.doi.org/10.1155/2016/2930414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059567/
https://www.ncbi.nlm.nih.gov/pubmed/27766105
http://dx.doi.org/10.1155/2016/2930414

Ejemplares similares